
<DOC>
<DOCNO>WT02-B18-148</DOCNO>
<DOCOLDNO>IA092-000988-B013-357</DOCOLDNO>
<DOCHDR>
http://www.cytrx.com:80/communications.html 206.216.36.35 19970110093445 text/html 4208
HTTP/1.0 200 OK
Date: Friday, 10-Jan-97 09:37:31 GMT
Server: WebSite/1.1
Allow-ranges: bytes
Accept-ranges: bytes
Content-type: text/html
Last-modified: Friday, 03-Jan-97 17:13:36 GMT
Content-length: 3993
</DOCHDR>
<head><TITLE>Communications</TITLE></HEAD>


<BODY background=/icons/wrich/bg.gif>
<BaseFont size=4>

<table width=95%><tr>
<td align=left>	
	<img src=/icons/cytrx.48pt.gif>
	</td>

<td align=right>
	<img src=/icons/multiopp.gif>
	</td>
</tr></table>
<img src=/icons/wrich/redline.gif>


<P>
<P>

<h1>Corporate Communications</h1>

<h2>Investor Relations Conference Calls</h2>
<img src=/icons/redball.gif> From <a href="call12_96.htm">12/9/96</a> Conference Call <br>
<p>
<img src=/icons/redball.gif> From <a href="call8_96.htm">8/27/96</a> Conference Call <br>
<p>
<img src=/icons/redball.gif> From <a href="confercallvet.html">2/6/96</a> Conference Call
<p>
<BR>

<B><FONT SIZE=5>Significant Events<BR>
</FONT></B>
<TABLE CELLPADDING=12 width=600>
<TR>
   <TD VALIGN=top><A  HREF="privy.htm">January</A></TD>
   <TD>CytRx's Vetlife subsidiary to replace Upjohn on January 1, 1997 as Ivy Laboratories 
exclusive North American marketing and distribution partner for line of FDA approved cattle growth products and devices.</TD>
</TR>
<TR>
   <TD VALIGN=top><A  HREF="proptivax.htm">January</A></TD>
   <TD>CytRx's Vaxcel subsidiary initiates a Phase I human clinical trial to evaluate the safety and activity 
of their Optivax&AElig; vaccine adjuvant in combination with a cancer vaccine in metastatic cancer patients.</TD>
</TR>
<TR>
   <TD VALIGN=top><A  HREF="prsplit.htm">February</A></TD>
   <TD>CytRx shareholders overwhelmingly approve one-for-four reverse stock split to better position CytRx in the financial markets.</TD>
</TR>
<TR>
   <TD VALIGN=top><A  HREF="prcorixa.htm">April</A></TD>
   <TD>Vaxcel licenses Optivax to Corixa Corporation for use in combination with Corixa's cancer and 
infectious disease vaccines that are under development.</TD>
</TR>
<TR>
   <TD VALIGN=top><A  HREF="prpatent.htm">June</A></TD>
   <TD>CytRx is awarded a composition of matter patent on RheothRx<I><SUB>pf, </SUB></I>a new purified form of 
RheothRx that removed the byproducts that were associated with renal side effects seen in earlier clinical trials.</TD>
</TR>
<TR>
   <TD VALIGN=top><A  HREF="prpatent.htm">July</A></TD>
   <TD>CytRx announces plans to commence an advanced human clinical trial in early 1997 to study 
RheothRx<I><SUB>pf </SUB></I> in patients suffering acute crises caused by sickle cell disease.</TD>
</TR>
<TR>
   <TD VALIGN=top><A  HREF="prelanco.htm">September</A></TD>
   <TD>Vetlife signs agreement with Eli Lilly's Elanco Animal Health division to become Elanco's 
exclusive U.S. supplier of its controlled-release Compudose Cattle Growth Implants.  Sales commence October 1.</TD>
</TR>
<TR>
   <TD VALIGN=top><A  HREF="prstock.htm">October</A></TD>
   <TD>CytRx announces it has bought  4.4% of its outstanding stock since initiating a stock repurchase plan in late 1995 -- 
a move underscoring CytRx's confidence in the value of its multiple opportunities.</TD>
</TR>
<TR>
   <TD VALIGN=top><A  HREF="prstock.htm">October</A></TD>
   <TD>CytRx reports third quarter revenues up 82% and loss per share down 40% versus the same period in 1995.</TD>
</TR>
<TR>
   <TD VALIGN=top><A  HREF="prmax.htm">November</A></TD>
   <TD>Max Link, an internationally recognized pharmaceutical executive, joins CytRx Board of Directors.</TD>
</TR>
<TR>
   <TD VALIGN=top><A  HREF="prvaxcel.htm">December</A></TD>
   <TD>Vaxcel to merge with Zynaxis, Inc. to create pubic company with multiple novel vaccine delivery opportunities.  
CytRx will own 87% of the “new” Vaxcel which will trade on the NASDAQ SmallCap Market.</TD>
</TR>
</TABLE>
<P>
<BR>
<p>

<img src="/icons/rain_line.gif">
<P>
<basefont>
<b>
[ <a href="/index.html">Home</a> 
| <a href="http://www.titermax.com">TiterMax</a> 
| <a href="/financial/overview.html">Investor Info</a> 
| <a href="/communications.html">Communications</a> 
| <a href="/adproceu.html">Proceutics</a> 
] </b>
<P>
<BR>

</body>
 
</DOC>